In a third trial (Rocha et al. 2015) the early MetS group had a significant reduction in CD34+/KDR+ and CD133+/CD34+/KDR+ EPC levels after a bout of MICON compared with their age-matched healthy control group. The gene discussed is PROM1; the disease is metabolic syndrome.